Dr Reddys Laboratories Ltd Share Price
(DRREDDY)
₹1163.6▲0.45%
as on 04:01PM, 17 Apr 2025
Dr Reddy's Laboratories Performance
Day's Low
Day's High
₹1,150.1Day's Price Range₹1,173.652 Week's Low
52 Week's High
₹1,02052-Week Price Range₹1,421.49
| Returns % | |
| 1 Month Return | -0.01 % |
| 3 Month Return | -10.65 % |
| 1 Year Return | -2.34 % |
| Market Stats | |
| Previous Close | ₹1,158.40 |
| Open | ₹1,150.10 |
| Volume | 27.88L |
| Upper Circuit | ₹1,274.20 |
| Lower Circuit | ₹1,042.60 |
| Market Cap | ₹97,097.23Cr |
Dr Reddy's Laboratories Fundamentals
P/E Ratio
18.04
PEG Ratio
11.07
Market Cap
₹97,097.23 Cr
P/B Ratio
4.22
EPS
66.882
Dividend Yield
0.65
Sector
Pharmaceuticals
ROE
19.42
Mutual Fund Holdings of Dr Reddy's Laboratories
Dr Reddy's Laboratories Analyst Rating
based on 38 analysts
36.84%
Buy
26.32%
Hold
36.84%
Sell
Based on 38 analysts offering long term price targets for Dr Reddy's Laboratories. An average target of ₹1326.5
Source: S&P Global Market Intelligence
Dr Reddy's Laboratories Share analysis
Dr Reddy's Laboratories price forecast by 38 analysts
Upside of14.00%
High
₹1723
Target
₹1326.50
Low
₹943
Dr Reddy's Laboratories target price ₹1326.5, a slight upside of 14% compared to current price of ₹1163.6. According to 38 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Dr Reddy's Laboratories revenue growth forecast
Expected growth rate Q1, FY2027:25.02%
Forecast
Actual
Including amortisation and stock based compensations
Dr Reddy's Laboratories EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Faces Challenges Amidst Growth Plans - 16 Apr, 2025
Dr. Reddy's Laboratories maintains a strong position in the U.S. generics market, focusing on complex generics. However, the stock has declined 8% over the past year, with unchanged EPS estimates for fiscal 2026. The company holds a Zacks Rank #3 (Hold).Dr Reddy’s Shares Rise Amid Denials and Acquisitions - 15 Apr, 2025
Dr Reddy’s Laboratories shares experienced a rise following the company's denial of workforce cut rumors and positive brokerage ratings. The company is also in discussions to acquire Sanofi's Lantus. Overall, the stock showed strong performance amid increased trading volume and positive financial indicators.Dr Reddy's Denies Workforce Cost Reduction Claims - 14 Apr, 2025
Dr Reddy's Laboratories has categorically denied media reports about a 25% workforce cost reduction, labeling them as factually incorrect. The company emphasized it does not comment on market speculations.Dr Reddy's Laboratories Implements Major Downsizing - 13 Apr, 2025
Dr Reddy's Laboratories is reducing workforce costs by 25%, potentially laying off 300-400 employees, primarily those in higher salary brackets. This move aims to offset margin pressures from declining Revlimid sales while maintaining operational efficiency and double-digit growth.Dr Reddy's Faces Tax Demand of Rs 2,396 Crore - 11 Apr, 2025
Dr Reddy's Laboratories received a show-cause notice from tax authorities demanding Rs 2,396 crore, linked to a tax issue from its 2022 merger with Dr Reddy's Holding Ltd.Dr Reddy's Reports Profit Amid Stock Decline - 10 Apr, 2025
Dr Reddy's Laboratories reported a Q3 net profit of Rs 27.9 crore, recovering from a loss last year. However, the stock fell 3.11% following the results amid broader pharma sector declines due to tariff concerns.Dr Reddy's Faces Tariff Concerns Amid IT Partnership - 09 Apr, 2025
Dr Reddy's Laboratories faces a 4% stock decline following Trump's tariff announcement on pharmaceuticals. Meanwhile, the company partners with Kyndryl to improve IT operations using AI technology.Dr. Reddy's Faces Tax Notice Amid Earnings Report - 05 Apr, 2025
Dr. Reddy's Laboratories reported a 14.7% revenue increase in Q3 FY25. The company also received a ₹2,395 crore tax reassessment notice related to a merger, asserting compliance with tax laws and plans to respond appropriately.Dr Reddy's Laboratories Faces Mixed Performance - 04 Apr, 2025
Dr Reddy's Laboratories shares have declined 19.5% YTD and 17% over six months, but long-term returns remain positive. Domestic sales are expected to grow 21% YoY, driven by the Sanofi portfolio integration, while US sales growth is projected at only 3% YoY in Q4FY25.Dr Reddys Shares Surge on US Tariff Relief - 03 Apr, 2025
On April 3, 2025, Dr Reddys Laboratories shares rose significantly as US President Trump excluded pharmaceuticals from new tariffs, leading to a 5% increase. The overall sentiment in the pharma sector was positive, with stocks opening higher and gaining throughout the day.Dr Reddy's Faces Margin Pressure from Tariffs - 02 Apr, 2025
Dr Reddy's Laboratories is likely to experience margin pressure due to potential tariff increases affecting export costs, particularly given its high reliance on the US market.Concerns Over Tariffs Impacting Pharma Sector - 30 Mar, 2025
India's 10% tariff on US pharma imports raises concerns among industry groups, highlighting potential cost burdens for distributors and generic manufacturers amid minimal US duties.Dr Reddys Partners with Bio-Thera for Biosimilars - 26 Mar, 2025
Dr Reddys Laboratories has entered into commercialization and licensing agreements with Bio-Thera Solutions for two proposed biosimilars, BAT2206 and BAT2506, targeting Southeast Asian markets and gaining exclusive rights in Colombia.Dr Reddys Schedules Meeting, Completes Facility Sale - 24 Mar, 2025
Dr Reddys Laboratories has scheduled a board meeting for May 9 to discuss financial results and dividends. Additionally, its subsidiary has finalized the sale of its Louisiana manufacturing facility.Dr Reddys Sells Louisiana Subsidiary - 23 Mar, 2025
Dr Reddys Laboratories has finalized the sale of its wholly owned subsidiary, Dr. Reddys Laboratories Louisiana LLC, including its manufacturing facility in Shreveport, Louisiana.Dr. Reddys Advances Biosimilar Development and Share Buying - 18 Mar, 2025
Dr. Reddys Laboratories and Alvotech received FDA acceptance for AVT03, a biosimilar to Prolia® and Xgeva®. They also signed a License Agreement for its development. Additionally, the company reported significant net buying of shares.
Insights on Dr Reddys Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 10.86% to 11.14% in Dec 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 7.31K Cr → 8.53K Cr (in ₹), with an average increase of 5.0% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 1.25K Cr → 1.41K Cr (in ₹), with an average increase of 11.2% per quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 9.97% to 10.22% in Dec 2024 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 26.64% of holdings in Dec 2024 quarter
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 27.53% to 26.85% in Dec 2024 quarter
Dr Reddy's Laboratories News
Suzlon Energy Stock Analysis: Is It a Buy After 16% Drop in 2025?
One of the most buzzing multibagger stocks, Suzlon Energys share price has fallen 16% in 2025 so far. The stock has been a multibagger over the long run. In the past 1 year, it has delivered returns of over 33%, though it had corrected significantly in the Covid times. The stock used to trade around Rs 1.90 in March 2020 but has consistently held over the Rs 50 a share mark in the near term. According to Motilal Oswal, it sees upside of 21% in the stock price from current levels and has placed the target price at Rs 70 per equity share. JM Financial Institutional Securities maintained a Buy call on Suzlon with a target of Rs 71 per equity share, implying an upside of 24% from the current levels. Suzlon remained upbeat about the revival as the companys order book was at the highest ever levels. Further, JM Financial sees the initiatives to enhance capabilities to handle more volume and higher-rating WTGs as a positive. The brokerage house believes that Suzlon is trading favourably on the earnings front as well. It is trading at an estimated price-to-earnings growth (PEG) ratio of 0.6 times for FY26. Suzlon has an installed base of 15 GW, holding a 31% market share of Indias total wind capacity of 48.2 GW as of Q3 FY25. The company is yet to report its Q4 FY25 earnings. Suzlon has a 31% cumulative market share in Indias wind energy sector. Suzlon Energys retail ownership rose to 25.12% Q4 FY25, up from 24.49% in the last quarter or Q3 FY25, as per BSE shareholding data. The share price of Suzlon Energy has risen almost 6% in the last five trading days. The stock has given a return of 0.2% in the past one month. However, the stock has erased almost 24% of the investors wealth in the previous six months. Suzlon Energys share price has increased by 34% in the past one year.18 Apr, 2025 01:37 PMTop Gainers and Losers on April 17: Market Movements
Suzlon Energy stock jumps 2% on bagging 100.8 MW order from Sunsure Energy. The project is set to be executed in Maharashtras Jath region and marks the global energy solutions providers maiden foray into wind energy segment and contribute to its objective of delivering Round-The-Clock power.17 Apr, 2025 06:04 PMSuzlon Energy Secures 100.8 MW Wind Power Order from Sunsure Energy
Suzlon has secured a 100.8 MW EPC wind power order from Sunsure Energy, marking their maiden foray into wind energy. The project is set to be executed in Maharashtras Jath region. As part of this agreement, Suzlon will supply 48 advanced S120 wind turbine generators (WTGs) featuring Hybrid Lattice Towers (HLTs), each bearing a capacity of 2.1 MW. Suzlons aspect includes supplying wind turbines, equipment installation oversight, and full project execution, along with erection and commissioning. Additionally, Suzlon will provide end-to-end operations and maintenance services following commissioning. This project will strengthen Sunsure Energys renewables portfolio and contribute to its objective of delivering Round-The-Clock power to users in the state of Maharashtra. Suzlon is enhancing the adoption of renewable energy among large corporations by partnering with Independent Power Producers (IPPs), playing a key role in supporting Indias clean energy transition. This initiative aligns with the countrys futuristic target of achieving 500 GW of non-fossil fuel capacity by 2030. Increasingly, Independent Power Producers (IPPs) are recognising winds potential to make power more accessible, affordable, and high‐ quality. This transition not only supports our energy goals but also drives sustainable economic growth and innovation across the industry, stated JP Chalasani, CEO, Suzlon Energy. Over the past year, Suzlon Energys stock has risen around 34 percent, as against a 8 percent gain in the benchmark Nifty 50.17 Apr, 2025 04:07 PMDr Reddy's Laboratories Financials
Dr Reddy's Laboratories Index Inclusions
Dr Reddy's Laboratories Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 26.64% | 0.00 | |
| Foreign Institutions | 26.85% | ||
| Mutual Funds | 11.14% | 2.57 | |
| Retail Investors | 10.22% | 2.49 | |
| Others | 25.15% | 0.64 |
Dr Reddy's Laboratories Key Indicators
Dr Reddy's Laboratories Valuation
Dr Reddy's Laboratories in the last 5 years
Lowest (3.37x)
October 27, 2019
Today (18.04x)
April 17, 2025
Industry (53.02x)
April 17, 2025
Highest (53.88x)
December 18, 2020
Dr Reddy's Laboratories Earnings and Dividends
Dr Reddys Laboratories Ltd Earnings Results
Dr Reddys Laboratories Ltd’s net profit jumped 2.38% since last year same period to ₹1,413.70Cr in the Q3 2024-2025. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated 12.58% jump in its net profits since last 3-months.
Read More about Earnings ResultsDr Reddys Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Dr Reddys Laboratories Ltd has declared dividend of ₹40 - translating a dividend yield of 6.88%.
Read More about Dividends
Dr Reddy's Laboratories Technicals Summary
Bearish
Neutral
Bullish
Dr Reddys Laboratories Ltd is currently in a Bullish trading position according to technical analysis indicators.
Dr Reddy's Laboratories Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹97,097.23 Cr | 10.26% | 0.52 | ₹5,577 Cr | ₹28,011 Cr | |
| HOLD | ₹1,49,724.28 Cr | 28.15% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,10,152.27 Cr | 35.85% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹39,775.88 Cr | -1.49% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹23,879.80 Cr | -4.07% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Dr Reddy's Laboratories
Dr Reddy's Laboratories Ltd has a diverse portfolio of products and services, including prescription drugs, generic drugs, over-the-counter drugs, active pharmaceutical ingredients, biotechnology products, and nutraceuticals. Its most popular products include antibiotics, anti-infectives, anti-diabetics, anti-cancer, cardiovascular, gastrointestinal, and dermatology products. Some of its popular brands include Omez, Ciprocin, and Revital. It also has a strong presence in the generics market with its brands such as Reditux and Reditux-D.
Revenue: ₹8,358.60Cr as on December 2024 (Q4 24)
Net Profit: ₹1,404.20Cr as on December 2024 (Q4 24)
Listing date: 03 Nov, 1994
Chairperson Name: K Satish Reddy
| Organisation | Dr Reddy's Laboratories |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Dr Reddys Laboratories Ltd
What is Dr Reddys Laboratories Ltd price today?
Dr Reddys Laboratories Ltd share price today stands at ₹1163.6, Open: ₹1150.1, Previous Close: ₹1158.4, High: ₹1173.6, Low: ₹1150.1, 52 Week High: ₹1421.49, 52 Week Low: ₹1020.
How to Buy Dr Reddys Laboratories Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Dr Reddys Laboratories Ltd shares
What are today's traded volumes of Dr Reddys Laboratories Ltd?
Today's traded volume of Dr Reddys Laboratories Ltd(DRREDDY) is 27.88L.
What is today's market capitalisation of Dr Reddys Laboratories Ltd?
Today's market capitalisation of Dr Reddys Laboratories Ltd(DRREDDY) is ₹97097.23Cr.
What is the 52 Week High and Low Range of Dr Reddys Laboratories Ltd?
How much percentage Dr Reddys Laboratories Ltd is down from its 52 Week High?
Dr Reddys Laboratories Ltd (DRREDDY) share price is ₹1163.6. It is down -18.14% from its 52 Week High price of ₹1421.49
How much percentage Dr Reddys Laboratories Ltd is up from its 52 Week low?
Dr Reddys Laboratories Ltd (DRREDDY) share price is ₹1163.6. It is up 14.08% from its 52 Week Low price of ₹1020